en
Scientific article
English

Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials

Published inThrombosis Research, vol. 149, p. 29-37
Publication date2017
Abstract

The results of the EINSTEIN-DVT/PE and AMPLIFY trials, which compared rivaroxaban and apixaban with conventional anticoagulation therapy for acute venous thromboembolism (VTE), respectively, are often compared. However, the trials differed in duration of therapy (3-12 and 6months, respectively) and in patient selection (few exclusion criteria and more stringent exclusion criteria, respectively).

Keywords
  • Adult
  • Aged
  • Cohort Studies
  • Factor Xa Inhibitors/administration & dosage/adverse effects/therapeutic use
  • Female
  • Hemorrhage/chemically induced
  • Humans
  • Male
  • Middle Aged
  • Patient Selection
  • Pyrazoles/administration & dosage/adverse effects/therapeutic use
  • Pyridones/administration & dosage/adverse effects/therapeutic use
  • Rivaroxaban/administration & dosage/adverse effects/therapeutic use
  • Treatment Outcome
  • Venous Thromboembolism/drug therapy
Citation (ISO format)
BEYER-WESTENDORF, Jan et al. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. In: Thrombosis Research, 2017, vol. 149, p. 29–37. doi: 10.1016/j.thromres.2016.11.014
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0049-3848
444views
1downloads

Technical informations

Creation01/08/2018 2:05:00 PM
First validation01/08/2018 2:05:00 PM
Update time03/15/2023 7:45:25 AM
Status update03/15/2023 7:45:23 AM
Last indexation01/17/2024 2:03:28 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack